Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin코로나19, 폐결핵, 인간면역결핍바이러스의 비정상적인 연관성, 클로로퀸과 리팜핀 치료에서 유리하게 진행Case Reports Published on 2020-07-132022-09-10 Journal: The Pan African Medical Journal [Category] MERS, SARS, 치료제, [키워드] addition anti-tubercular agents aspect association Chain Reaction chest CT scan Chloroquine Clinical improvement clinical trials Control coronavirus Course COVID-19 curative treatment described Deterioration drug drugs Effectiveness enzyme flu general condition health emergency HIV HIV serology Human immunodeficiency virus immunodeficiency virus inducer Infection inhibiting International international health Isolation lung Messenger RNA messenger RNAs miliary tuberculosis Nasopharyngeal swab New coronavirus Patient PCR positive progressed pulmonary tuberculosis reduce respiratory rifampin SARS-ncov-2 sputum subject Symptom synergistic synergistic effect therapeutic Treatment trifecta Tuberculosis [DOI] 10.11604/pamj.supp.2020.35.2.24952 PMC 바로가기 [Article Type] Case Reports
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral TherapyTAILoR(인간 면역결핍 바이러스[HIV]의 TelmisArtan 및 InsuLin 내성): 복합 항레트로바이러스 요법을 받는 HIV 양성 환자의 인슐린 내성 감소를 위한 Telmisartan의 적응형 설계, 용량 범위 IIb상 무작위 시험Articles and Commentaries Published on 2020-05-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] adaptive Analysis antiretroviral drugs Antiretroviral therapy Antiretrovirals ARMS cardiovascular disease check clinical Combination conducted Controlled trial demonstrated Efficacy evaluated fat had no HIV HIV infection homeostasis Human Human immunodeficiency virus identify IIb immunodeficiency virus improvement Improvements index individual Infection insulin insulin resistance Insulin sensitivity interim analysis Intervention investigated ISRCTN liver longitudinal longitudinal analysis measure metabolic abnormalities Metabolic abnormality metabolic disease morbidity and mortality multicenter no difference no differences no significant effect once daily Open-label participant Patient phase plasma Primary outcome primary outcome measure Randomized receiving recruited reduce reduction in Registration resistance Result risk secondary outcome measures significant effect Stage stage II telmisartan Trial with HIV [DOI] 10.1093/cid/ciz589 PMC 바로가기 [Article Type] Articles and Commentaries
Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa남아프리카 공화국의 HIV 예방 시험 네트워크 071(PopART) 시험에서 인간 면역 결핍 바이러스(HIV)를 가지고 사는 사람들 사이에서 더 나은 바이러스학적 결과가 조기 항레트로바이러스 치료(CD4 카운트 ≥500 세포/μL)를 시작합니다Articles and Commentaries Published on 2020-02-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] adjusted hazard ratio adjusted relative risk Antiretroviral therapy ART baseline CD4 baseline CD4 cell baseline CD4 cell count Better CD4 CD4 count CD4 counts clinical clinically confidence interval count early antiretroviral treatment elevated hazard ratio HIV HIV/AIDS HPTN 071 (PopART) Trial Human Human immunodeficiency virus immunodeficiency virus implementation incidence rate Initiating International interval National network participant Participants pre-ART CD4 pre-ART CD4 cell prevention prospective cohort study provided reduced Registration Relative risk Result risk South Africa Trial universal ART Viral Viral load virological failure virological outcome virological outcomes virological suppression [DOI] 10.1093/cid/ciz214 PMC 바로가기 [Article Type] Articles and Commentaries
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study인간 면역 결핍 바이러스의 위험이 있는 젊은이들 사이에서 노출 전 예방에 대한 유지 및 준수를 촉진하기 위한 모바일 건강 중재의 무작위 대조 시험: EPIC 연구Articles and Commentaries Published on 2019-06-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 95% CI 95% confidence interval acquisition adherence age bidirectional Blood clinical Concentration conducted Controlled demonstrated doses drug levels Effectiveness Efficacy enrolled EpiC evaluate evaluated HIV Human Human immunodeficiency virus immunodeficiency virus individual Infection insurance Intervention Latino Logistic men men who have sex with men (MSM) Mobile not differ Odds ratio outcome participant preexposure prophylaxis preexposure prophylaxis (PrEP) PrEP Prophylaxis Randomized Randomized controlled trial receive Registration reported Result retention risk robust Sex significantly significantly increased SOC Standard of care study visit tenofovir tenofovir diphosphate text-messaging TFV-DP Youth [DOI] 10.1093/cid/ciy810 PMC 바로가기 [Article Type] Articles and Commentaries
Liver as a target of human immunodeficiency virus infectionReview Published on 2018-11-142023-06-17 Journal: World journal of gastroenterology [Category] B형 간염, [키워드] alcohol Antiretroviral therapy Apoptosis fibrosis immunodeficiency virus Inflammation Liver cells. [DOI] 10.3748/wjg.v24.i42.4728 PMC 바로가기 [Article Type] Review
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial신생아 MVA85A 백신 접종 및 인간 면역결핍 바이러스에 감염된 산모의 유아를 위한 선택적 지연 Bacille Calmette-Guerin의 안전성 및 면역원성: 2상 무작위, 대조 시험Articles and Commentaries Published on 2018-02-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] acquisition Ag85A age appear ARMS bacille Calmette-Guérin BCG BCG vaccination boost candidate CD4 CD4+ T cell CD4+ T cells CD4+ T-cell clinical control arm Controlled Delayed disease double-blind ENhance enrolled excluded Follow-up followed by functional HIV HIV infection HIV-exposed infants HIV-uninfected Human Human immunodeficiency virus IFNγ immune response immunodeficiency virus immunogenicity Infant interfere interferon gamma life magnitude memory MVA85A New Newborn no significant difference Phase 2 phenotype potential risk profiles PROTECT randomized, controlled trial reactogenicity event Registration response Result Safe Safety selective Serious Adverse Events significantly higher subsequent T cells T-cell Response tested Tuberculosis tuberculosis disease tuberculosis vaccine vaccination Vaccination strategy vaccinees [DOI] 10.1093/cid/cix834 PMC 바로가기 [Article Type] Articles and Commentaries
Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials임산부의 인플루엔자 바이러스 감염률 및 백신 효능 평가에서 혈청학적 분석의 기여: 무작위 대조 시험의 보고서Major Article Published on 2017-06-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 95% CI 95% confidence interval Analysis antibody collected Controlled defined diagnosed diagnostic during pregnancy Efficacy episode of evaluate Evidence evidence of exposure to greater hemagglutination inhibition assay. HIV-uninfected Human immunodeficiency virus immunodeficiency virus immunogenicity inactivated incidence increase in Influenza influenza infection influenza vaccine Influenza virus molecular pharyngeal phase III trial placebo recipients polymerase chain polymerase chain reaction post-hoc analysis postvaccination Pregnancy pregnant pregnant women Prevent prevented provided randomized clinical trial Rate report required Seasonal influenza serologic serologic testing Serologically specimen utility vaccination Vaccine vaccine efficacy virus women [DOI] 10.1093/cid/cix241 PMC 바로가기 [Article Type] Major Article
The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis치료적 요추 천자가 크립토코커스 수막염으로 인한 급성 사망률에 미치는 영향HIV/AIDS Published on 2014-12-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] acute mortality adjusted relative risk Altered mental status ART association baseline cerebrospinal fluid COAT trial Conducting cryptococcal meningitis Cryptococcal Optimal ART Timing cryptococcosis CSF CSF fungal death diagnose Diagnosis Effect elevated Epidemiology Follow-up HIV Human immunodeficiency virus ICP immunodeficiency virus individual initial initial pressure intracranial pressure investigated Lumbar puncture lumbar punctures magnitude management Meningitis Mortality occurred Patient randomization Randomized receiving Relative risk risk screened South Africa sub-Saharan Africa subject subsequent survival Symptoms therapeutic LP therapeutic LPs therapeutic lumbar punctures time of death Trial Uganda was related [DOI] 10.1093/cid/ciu596 PMC 바로가기 [Article Type] HIV/AIDS
SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral RegimenSWIFT: 항레트로바이러스 요법을 포함하는 강화된 프로테아제 억제제를 사용하는 바이러스학적으로 억제된 HIV-1 감염 환자에서 라미부딘/아바카비르에서 엠트리시타빈/테노포비어로 전환하는 것의 효능 및 안전성을 평가하기 위한 전향적 48주 연구HIV/AIDS Published on 2013-06-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 3TC/ABC 95% confidence interval abacavir addition Arm ARMS backbone baseline characteristics calculated CD4 Characteristics cholesterol compared Containing Decline decrease Decreased defined Efficacy and safety EGFR emtricitabine emtricitabine/tenofovir epidermal epidermal growth factor evaluate FTC/TDF fumarate GFR greater growth factor HIV patient HIV patients HIV-1 Human immunodeficiency virus immunodeficiency virus improvement Improvements Infected inhibitor lamivudine LDL Lipid lipids Lipoproteins Low-density lipoprotein low-density lipoproteins male median median age nucleoside Open-label parameter Patient PI primary endpoint Prospective Protease inhibitor Randomized rebound receiving receptor regimen reverse transcriptase risk score Ritonavir RNA RTV Safety study drug subject suppressed switch switching tenofovir disoproxil fumarate TG The United States threshold Total cholesterol transcriptase treated treatment difference Triglyceride triglycerides United States virologic failure Virologic suppression [DOI] 10.1093/cid/cis1203 PMC 바로가기 [Article Type] HIV/AIDS
Towards a Coronavirus-Based HIV Multigene VaccineResearch Article Published on 2006-01-012022-10-31 Journal: Clinical and Developmental Immunology [Category] Coronavirus, [키워드] Adults aminopeptidase N anti-HIV drug antigen presenting cell antigens cause CD13 children common cold coronavirus Coronavirus infection costly DC DCs dendritic cell Efficiency enteric diseases expressed feature Gene Gene Expression HCoV 229E Health Heterologous HIV Human human coronavirus 229E humans immunodeficiency virus infected individual infecting Infection Macrophage Molecular biology mucosal surfaces occur pre-existing immunity Prevent Re-infection receptor replaced required RNA second significantly Spread These cells threat transcriptional Transmission Treatment upper respiratory tract vaccination Vaccination strategy Vaccine Vaccines vector Virus-like particle VLPs [DOI] 10.1080/17402520600579168 PMC 바로가기 [Article Type] Research Article